Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial
By Aebra Coe · June 7, 2021, 7:55 PM EDT
The $466 million an Israeli subsidiary of Irish drugmaker Perrigo Co. earned from sales of a heartburn medication "in no way can possibly comply" with transfer pricing law, an economist said Monday during the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login